


03701 1134

JOURNAL OF NEUROCHEMISTRY

OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY



RAVEN PRESS

Page 1 of 6

JAZZ EXHIBIT 2002

Ranbaxy Inc. (Petitioner) v. Jazz Pharms. Ireland Ltd. (Patent Owner)

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

JOURNAL OF NEUROCHEMISTRY

CHIEF EDITORS

H. S. Bachelard, *Department of Biochemistry, St. Thomas's Hospital Medical School, London SE1 7EH, U.K.*

W. T. Norton, *Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, U.S.A.*

DEPUTY CHIEF EDITORS

M. H. Aprison, *Institute of Psychiatric Research, Indiana University School of Medicine, 1100 West Michigan Street, Indianapolis, IN 46223, U.S.A.*

F. Fonnum, *Norwegian Defence Research Establishment, Division of Toxicology, P.O. Box 25, N-2007 Kjeller, Norway*

R. W. Ledeen, *Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, U.S.A.*

R. E. Martenson, *Laboratory of Cerebral Metabolism, Building 36, Room #1A-27, National Institutes of Health, Bethesda, MD 20205, U.S.A.*

K. F. Tipton, *Department of Biochemistry, Trinity College, University of Dublin, Dublin 2, Ireland*

EDITORIAL BOARD

B. W. Agranoff (*Ann Arbor, MI*)

S. H. Appel (*Houston, TX*)

R. L. Barchi (*Philadelphia, PA*)

E. A. Barnard (*London*)

C. F. Baxter (*Sepulveda, CA*)

N. G. Bazan (*New Orleans, LA*)

S. Berl (*New York, NY*)

J. P. Blass (*White Plains, NY*)

E. Bock (*Copenhagen*)

A. Boulton (*Saskatoon*)

M. J. Brammer (*London*)

P. R. Carnegie (*Victoria*)

B. Collier (*Montreal*)

J. R. Cooper (*New Haven, CT*)

C. Cotman (*Irvine, CA*)

M. Cuénod (*Zurich*)

G. Curzon (*London*)

I. Diamond (*San Francisco, CA*)

T. E. Duffy (*New York, NY*)

Y. Dunant (*Geneva*)

P. Emson (*Cambridge*)

L. F. Eng (*Palo Alto, CA*)

H. Gainer (*Bethesda, MD*)

G. Gombos (*Strasbourg*)

D. I. Gottlieb (*St. Louis, MO*)

A. Hamberger (*Göteborg*)

M. Hamon (*Paris*)

B. Hamprecht (*Würzburg*)

G. Hauser (*Belmont, MA*)

F. A. Henn (*Iowa City, IA*)

L. Hertz (*Saskatoon*)

J. G. Hildebrand (*New York, NY*)

L. Horrocks (*Columbus, OH*)

T. Johnson (*Manhattan, KS*)

S. Kakiuchi (*Osaka*)

J. N. Kanfer (*Winnipeg*)

M. J. Kuhar (*Baltimore, MD*)

M. Kurokawa (*Tokyo*)

M. B. Lees (*Waltham, MA*)

L. Lim (*London*)

G. G. Lunt (*Bath*)

R. M. Marchbanks (*London*)

R. U. Margolis (*New York, NY*)

J. Massoulié (*Paris*)

W. O. McClure (*Los Angeles, CA*)

B. S. McEwen (*New York, NY*)

E. McGeer (*Vancouver*)

P. Morell (*Chapel Hill, NC*)

D. Morris (*Southampton*)

S. J. Morris (*Bethesda, MD*)

S. R. Nahorski (*Leicester*)

M. Otsuka (*Tokyo*)

H. M. Pappius (*Montreal*)

J. V. Passonneau (*Bethesda, MD*)

G. Porcellati (*Perugia*)

S. B. Prusiner (*San Francisco, CA*)

R. H. Quarles (*Bethesda, MD*)

J. A. Richter (*Indianapolis, IN*)

P. J. Roberts (*Southampton*)

K. Sandhoff (*Bonn*)

J. C. Schwartz (*Paris*)

D. F. Sharman (*Babraham*)

M. L. Shelanski (*New York, NY*)

M. E. Smith (*Palo Alto, CA*)

J. Storm-Mathisen (*Oslo*)

H. Thoenen (*Martinsried*)

S. Tucek (*Praha*)

C. Van den Berg (*Groningen*)

S. Varon (*La Jolla, CA*)

M. Voaden (*London*)

N. Weiner (*Denver, CO*)

E. Yavin (*Rehovot*)

C. Zomzely-Neurath (*Honolulu, HI*)

INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY PUBLICATIONS COMMITTEE

M. H. Aprison (*Indianapolis, IN*)

H. S. Bachelard (*London*)

N. G. Bazan (*New Orleans, LA*)

L. Iversen (*Cambridge*)

T. Kato (*Tokyo*)

P. A. Kometiani (*Tbilisi*)

P. Mandel (*Strasbourg*)

W. T. Norton (*New York, NY*)

G. Porcellati (*Ex-Officio, Perugia*)

E. M. Shooter (*Stanford, CA*)

L. Sokoloff (*Bethesda, MD*)

K. Suzuki (*New York, NY*)

L. S. Wolfe (*Montreal*) (*Chairman*)

PUBLICATION AND ADVERTISING STAFF, RAVEN PRESS, NEW YORK

David A. Christie
Production Manager

Gretchen Berg
Secretary

Irene Rubinson
Advertising Manager

Journal of Neurochemistry (ISSN 0022-3042) is published monthly by Raven Press, 1140 Avenue of the Americas, New York, NY 10036. Second class postage paid at New York, N.Y. and at additional mailing offices. Subscription rates for 1982 (Vols. 38 and 39): members of International Society for Neurochemistry, \$57; institutional subscriptions, \$485; rate to any individual whose institutional library is a subscriber in 1982, \$168. Single copies, \$41. Air delivery included for European and Mediterranean countries; for air service elsewhere add \$96. Payment should accompany all orders. Please enclose present mailing label with all change of address requests. Address all advertising inquiries to Advertising Manager, Raven Press. Copyright © 1982 International Society for Neurochemistry Ltd. Postmaster: Send change of address to Subscription Department, Raven Press, 1140 Avenue of the Americas, New York, NY 10036. For additional copyright information, see back of issue.

Short Communication

Effects of Anticonvulsants on the Formation of γ -Hydroxybutyrate from γ -Aminobutyrate in Rat Brain

Susan R. Whittle and Anthony J. Turner

Department of Biochemistry, University of Leeds, Leeds, U.K.

Abstract: The conversion of γ -aminobutyrate (GABA) via succinic semialdehyde to γ -hydroxybutyrate has been examined in rat brain homogenates. A number of anticonvulsants, including sodium valproate and phenobarbitone, inhibited this metabolic pathway. These results are interpreted in the light of the characteristics of aldehyde reductases known to reduce succinic semialdehyde. **Key Words:** Aldehyde reductase—Anticonvulsants—Sodium valproate— γ -Hydroxybutyrate—GABA metabolism—Succinic semialdehyde. **Whittle S. R. and Turner A. J.** Effects of anticonvulsants on the formation of γ -hydroxybutyrate from γ -aminobutyrate in rat brain. *J. Neurochem.* **38**, 848–851 (1982).

Much attention has focussed on a role for γ -aminobutyrate (GABA) in the control of epileptic convulsions (Meldrum, 1975; Turner and Whittle, 1980). A disruption of metabolism that causes a fall in the synaptic concentration of GABA could lead to a decrease in neuronal inhibition resulting in seizures. Alternatively, the concentration of GABA may be normal but its postsynaptic action could be impaired. Anticonvulsants might restore the inhibitory response to normal by acting at either of these two levels. It has been known for some years that the anticonvulsant sodium valproate (Epilim[®], 2-propylpentanoate) inhibits the conversion of GABA to its major metabolite, succinate (Harvey et al., 1975; Sawaya et al., 1975). However, it appears unlikely that this inhibition would be effective at normal clinical doses of the drug (Whittle and Turner, 1978; Turner and Whittle, 1980; Kerwin and Taberner, 1981). An alternative route of metabolism of GABA involves its transamination to succinic semialdehyde followed by reduction to γ -hydroxybutyrate. This compound is apparently capable of inducing an epileptic-like state in animals (Marcus et al., 1967; Snead et al., 1976). Thus alterations in brain levels of γ -hydroxybutyrate may affect the seizure threshold and are a potential site of action for valproate and similar compounds (Turner and Whittle, 1980; Kerwin and Taberner, 1981).

The enzyme(s) responsible for the reduction of succinic

semialdehyde to γ -hydroxybutyrate may be related to the family of NADPH-dependent aldehyde reductases (alcohol:NADP⁺ oxidoreductase, EC 1.1.1.2) (Kaufman et al., 1979). The major form of this enzyme has been shown to be very sensitive to inhibition by valproate, barbiturates, and some other anticonvulsants (Erwin and Dietrich, 1973; Whittle and Turner, 1978; 1981a,b; Javors and Erwin, 1980). Recently, however, a distinct reductase exhibiting high specificity and affinity for succinic semialdehyde has been reported to occur in brain (Cash et al., 1979; Hoffmann et al., 1980; Rumigny et al., 1980; Rivett et al., 1981). This latter enzyme is apparently insensitive to inhibition by anticonvulsants (Cash et al., 1979; Rumigny et al., 1980). The relative contribution of each of these reductases to the physiological production of γ -hydroxybutyrate from GABA has not been directly assessed. Clarification of the problem should reveal whether modifications in this metabolic pathway are relevant to the molecular actions of certain classes of anticonvulsants, as suggested elsewhere.

The concentration of succinic semialdehyde in brain is normally very low (approximately 10^{-10} mol/g brain—Matsuda and Hoshino, 1977). Several authors have therefore argued that the specific and 'high-affinity' succinic semialdehyde reductase would be the principal, if not exclusive, enzyme involved in γ -hydroxybutyrate formation from GABA (Hoffmann et al., 1980; Rumigny et

Received July 30, 1981; accepted September 25, 1981.

Address correspondence and reprint requests to Dr. A. J. Turner, Department of Biochemistry, University of Leeds, 9 Hyde Terrace, Leeds LS2 9LS, U.K.

Abbreviation used: GABA, γ -Aminobutyric acid.

al., 1981; Rivett et al., 1981). However, Anderson et al. (1977) have shown that barbiturates markedly inhibit γ -hydroxybutyrate formation *in vitro*, suggesting a significant role for the major aldehyde reductase in this process. These authors, though, used millimolar concentrations of succinic semialdehyde as substrate. To obtain a more realistic assessment of the rates of synthesis of γ -hydroxybutyrate, we examined the effects of anticonvulsants, valproate analogues, and other known aldehyde reductase inhibitors on the overall formation of γ -hydroxybutyrate from GABA in rat brain homogenates. Studies of this type have previously allowed us to assess the relative contribution of aldehyde reductase isoenzymes to the reductive metabolism of catecholamines (Whittle and Turner, 1981a).

MATERIALS AND METHODS

Sodium valproate was a gift from Dr. D. S. Walter, Reckitt & Colman Pharmaceutical Division, Hull. The flavonoid inhibitors quercetin and quercitrin were obtained respectively from Sigma Chemical Corp. and from I.C.N. Pharmaceuticals Inc., Piscataway, New Jersey, U.S.A. γ -Valerolactone was from Aldrich Chemical Co., Gillingham, U.K. GABA aminotransferase (4-aminobutyrate:2-oxoglutarate aminotransferase, EC 2.6.1.19) was purified from rat brain and assayed as described previously (Whittle and Turner, 1978).

Brains obtained from male Wistar rats (170–190 g) were homogenised in 1 volume of 0.1 M-sodium phosphate buffer, pH 7.0, and a sample (equivalent to 10 mg brain) was incubated at 37°C for 5 min in the presence of GABA (1 mM), 2-oxoglutarate (1 mM) and NADPH (0.1 mM). The reaction was terminated by the addition of 2 ml of trichloroacetic acid (50%, w/v). Denatured protein was removed by centrifugation and the supernatant was lyophilised. The residue was redissolved in 0.1 M-sodium

phosphate buffer, pH 7 (1 ml), and heated at 90°C for 10 min to convert the acid to a lactone derivative. After cooling on ice, the sample was adjusted to pH 6 and γ -valerolactone (2 μ g) was added as internal standard. The sample was then extracted twice with 2 volumes of chloroform, and the pooled chloroform extracts were evaporated to approximately 100 μ l before samples were quantitated by gas-liquid chromatography. The production of γ -hydroxybutyrate was linear with respect to time and protein concentration in the range tested. The recovery of product, determined by adding a known amount of γ -hydroxybutyrate to the brain homogenate followed by the normal extraction procedure, was $85 \pm 5\%$.

RESULTS

The uninhibited reaction produced $0.107 \pm 0.018 \mu$ g γ -hydroxybutyrate/min/g brain (wet weight) in the presence of NADPH. The reaction rate in the presence of added coenzyme was threefold that observed in its absence. NADH, however, produced no significant stimulation of reaction rate suggesting that the formation of γ -hydroxybutyrate from GABA is primarily NADPH-dependent. These data would be consistent with the report by Cash et al. (1979) that brain aldehyde reductases using succinic semialdehyde as substrate are NADPH-dependent.

The effects of a range of anticonvulsants and aldehyde reductase inhibitors on γ -hydroxybutyrate formation are listed in Table 1. Sodium valproate and its structural analogues, as well as phenobarbitone, all inhibited the reaction. The aldehyde reductase inhibitors quercetin and quercitrin also exerted significant inhibitory effects. The overall conversion of GABA to γ -hydroxybutyrate involves the action of GABA aminotransferase (EC 2.6.1.19) as well as aldehyde reductases. Thus, the effects of those compounds that inhibited γ -hydroxybutyrate

TABLE 1. Effects of anticonvulsants and valproate analogues on γ -hydroxybutyrate formation from GABA

Drug (1 mM)	γ -Hydroxybutyrate formed (μ g/min/g brain)	Inhibition (%)
None	0.107 ± 0.018 (9)	—
Anticonvulsants		
Sodium valproate	0.035 ± 0.002 (4)	67.3
Phenobarbitone	0.040 ± 0.008 (4)	62.6
Diphenylhydantoin	0.088 ± 0.021 (4)	17.8
Carbamazepine	0.095 ± 0.01 (4)	11.3
Phenacemide	0.080 ± 0.011 (4)	25.2
Valproate analogues		
Diphenylacetate	0.038 ± 0.003 (4)	64.5
2-Phenylbutyrate	0.041 ± 0.003 (4)	61.7
2-Ethylhexanoate	0.042 ± 0.003 (4)	60.7
Other aldehyde reductase inhibitors		
Quercetin	0.029 ± 0.009 (4)	72.9
Quercitrin	0.048 ± 0.014 (4)	55.1

Samples (1 μ l) obtained as described in the text were injected into a Varian Aerograph 1520 gas-liquid chromatograph containing a glass column (2 m \times 3 mm i.d.) packed with 6% diethyleneglycol-succinate on 100–120 mesh Phasesep NI DCMS, and connected to a flame-ionization detector. The temperature settings were 167°C, 128°C and 150°C for inlet, column and detector, respectively, and carrier gas (helium) flow rate was 35 ml/min. Retention times were 2.6 min for γ -valerolactone and 1.7 min for γ -hydroxybutyrate.

Results are means \pm S.D. for the numbers of animals indicated in parentheses.

TABLE 2. Effects of inhibitors of γ -hydroxybutyrate formation on the activity of GABA aminotransferase

Inhibitor	Rate (nmol/min/ml)	Inhibition (%)
None	6.11	—
Sodium valproate	5.6	8.4
Phenobarbitone	5.88	3.8
Diphenylacetate	5.95	2.6
2-Phenylbutyrate	5.63	7.9
2-Ethylhexanoate	5.80	5.1
Quercetin	5.95	2.1
Quercitrin	5.3	13.2

Rat brain GABA aminotransferase was purified and assayed as described for the enzyme from ox brain (Whittle and Turner, 1978). All inhibitors were maintained at 1 mM.

formation were also examined on the activity of the transaminase. None of the observed inhibitors of γ -hydroxybutyrate formation had a significant effect on the activity of purified GABA aminotransferase at the concentrations used in these studies (Table 2).

DISCUSSION

The present results suggest that the specific succinic semialdehyde reductase is not exclusively responsible for γ -hydroxybutyrate formation from GABA under the conditions used here, since this enzyme is reported to be unaffected by barbiturates and sodium valproate (Cash et al., 1979; Rumigny et al., 1980). It would appear that the nonspecific (anticonvulsant-sensitive) aldehyde reductase may also contribute to a significant extent to this metabolic pathway. These conclusions would not be inconsistent with the established data on the two reductases purified from rat brain. If it is assumed that the intracellular (noninulin) space in brain is 0.56 ml/g tissue (see e.g. Turner and Hick, 1975), then a value of approximately 1.8×10^{-7} M is obtained for normal intracellular concentrations of succinic semialdehyde (Matsuda and Hoshino, 1977). The specific reductase contributes 10–20% toward the total reductase activity in brain and both enzymes are cytosolic in location (Rumigny et al., 1980; 1981). The respective Michaelis constants for succinic semialdehyde are reported to be 28 μ M (specific reductase) and 140 μ M (nonspecific reductase), obtained with the purified enzymes from rat brain (Rumigny et al., 1980). Given these parameters, the nonspecific reductase would be expected to contribute more than 50% of the total activity toward succinic semialdehyde reduction at physiological concentrations of this substrate. Even at substantially lower concentrations of succinic semialdehyde, the nonspecific reductase would still make a significant contribution towards γ -hydroxybutyrate production, in agreement with our data (Table 1). We cannot at present, though, rule out the possibility that the specific succinic semialdehyde reductase may be localized in GABA-containing neurons.

Relatively high concentrations of sodium valproate compared with those in clinical use (Sawaya et al., 1975) are required to cause significant inhibition of γ -hydroxybutyrate formation (Table 1). Thus, it seems unlikely that valproate exerts its anticonvulsant effects through an action on this metabolic pathway. An alternative mode of action of valproate must therefore be postu-

lated. An effect of valproate on the postsynaptic membrane is an attractive proposition in view of recent neurophysiological studies suggesting that valproate augments the postsynaptic inhibitory effects of GABA (MacDonald and Bergey, 1979; Kerwin et al., 1980).

Acknowledgments: S.R.W. is Emma and Leslie Reid Fellow of the University of Leeds. This work was supported in part by the Medical Research Council.

REFERENCES

- Anderson R. A., Ritzmann R. F., and Tabakoff B. (1977) Formation of γ -hydroxybutyrate in brain. *J. Neurochem.* **28**, 633–639.
- Cash C. D., Maitre M., and Mandel P. (1979) Purification from human brain and some properties of two NADPH-linked aldehyde reductases which reduce succinic semialdehyde to 4-hydroxybutyrate. *J. Neurochem.* **33**, 1169–1175.
- Erwin V. G. and Dietrich R. A. Inhibition of bovine brain aldehyde reductase by anticonvulsant compounds *in vitro*. *Biochem. Pharmacol.* **22**, 2615–2624.
- Harvey P. K. P., Bradford H. F., and Davison A. (1975) The inhibitory effect of dipropylacetate on the degradative enzymes of the GABA shunt. *FEBS Lett.* **52**, 251–254.
- Hoffmann P. L., Wermuth B., and von Wartburg J. P. (1980) Human brain aldehyde reductases: Relationship to succinic semialdehyde reductase and aldose reductase. *J. Neurochem.* **35**, 354–366.
- Javors M. and Erwin V. G. (1980) Effects of benzodiazepines and valproic acid on brain aldehyde reductase and a proposed mechanism of anticonvulsant action. *Biochem. Pharmacol.* **29**, 1703–1708.
- Kaufman E. E., Nelson T., Goochee C., and Sokoloff L. (1979) Purification and characterization of an NADP⁺-linked alcohol oxidoreductase which catalyzes the interconversion of γ -hydroxybutyrate and succinic semialdehyde. *J. Neurochem.* **32**, 699–712.
- Kerwin R. W. and Taberner P. V. (1981) The mechanism of action of sodium valproate. *Gen. Pharmacol.* **12**, 71–75.
- Kerwin R. W., Olpe H.-R., and Schmutz M. (1980) The effects of sodium-n-dipropyl acetate on γ -aminobutyric acid-dependent inhibition in the rat cortex and substantia nigra in relation to its anticonvulsant activity. *Br. J. Pharmacol.* **71**, 545–551.
- MacDonald R. L. and Bergey G. K. (1979) Valproic acid augments GABA-mediated post-synaptic inhibition in cultured mammalian neurons. *Brain Res.* **170**, 558–562.
- Marcus R. J., Winters W. D., Mori K., and Spooner C. E. (1967) EEG and behavioural comparison of the effects of γ -hydroxybutyrate, γ -butyrolactone and short chain fatty acids in the rat. *Int. J. Neuropharmacol.* **6**, 175–185.
- Matsuda M. and Hoshino M. (1977) Natural occurrence of succinic semialdehyde in mouse brain. *Jikeikai Med. J.* **24**, 33–36.
- Meldrum B. S. (1975) Epilepsy and GABA mediated inhibition. *Int. J. Neurobiol.* **17**, 1–36.
- Rivett A. J., Smith A. L., and Tipton K. F. (1981) The enzymes catalysing succinic semialdehyde reduction in rat brain. *Biochem. Pharmacol.* **30**, 741–747.
- Rumigny J. F., Maitre M., Cash C., and Mandel P. (1980) Specific and non-specific succinic semialdehyde reductases from rat brain: Isolation and properties. *FEBS Lett.* **117**, 111–116.
- Rumigny J. F., Maitre M., Cash C., and Mandel P. (1981) Regional and subcellular localization in rat brain of the enzymes that can synthesize γ -hydroxybutyric acid. *J. Neurochem.* **36**, 1433–1438.
- Sawaya M. C. B., Horton R. W., and Meldrum B. S. (1975) Ef-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.